DJIA 17,812.19 19.51 0.11%
NASDAQ 5,102.81 0.33 0.01%
S&P 500 2,089.14 2.55 0.12%
market minute promo

Gilead Sciences (NASDAQ: GILD)

company name or ticker
Company Photos
(Click to zoom)

Tyco Q4 Earnings In Line with Estimates, Revenues Lag

3 Stocks Dragging In The Drugs Industry

Gilead: Like Watching Paint Dry In 2015

Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?

Big names are promising big plays in hepatitis C cures

Gilead: The Margin Of Safety Will Benefit Long-Term Investors

Isis Moves Closer To A Durable Success

The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem


A Trio of Catalysts Lift Merck Higher in October

FDA approvals, hepatitis C combo data finding the mark, and a better-than-expected earnings report -- oh my!

Short Sellers Run for Cover From Major Biotechs

See More Articles...